Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $196
AbbVie, Inc. +1.56%
AbbVie, Inc. ABBV | 196.42 | +1.56% |
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:
ABBV) with a Overweight and raises the price target from $193 to $196.
